Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

World Journal of Surgical Oncology

Caigang Liu³  Deyan Pang²  Yuan Ren¹  Hao Zhang³ 

[1] Department of Hematology, First hospital of China Medical University, Nanjing Street, Shenyang 110001, People’s Republic of China;Department of Mathematics, Northeast Yucai School, Shiji Road, Shenyang 110179, People’s Republic of China;Department of Breast Surgery, Second hospital of Dalian Medical University, Zhongshan Road, Dalian 116023, People’s Republic of China

关键词: Survival;    latexin;    AGBL2;    Cancer stem cell;    Breast cancer;   

Others  :  811872
DOI  :  10.1186/1477-7819-12-142

 received in 2013-08-31, accepted in 2014-04-20,  发布年份 2014

【 摘 要 】

Background

We investigated the expression status of AGBL2 and its inhibitor latexin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer.

Methods

CD44+/CD24- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. AGBL2 expression status was detected in CSC and 126 breast cancer specimens by western blot and immunohistochemistry staining. The relationship between the AGBL2 protein and clinicopathological parameters and prognosis was subsequently determined.

Result

As a result, CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in non-obese diabetic/severe combined immunodeficiency mice (NOD/SCID) compared to the control group. The AGBL2 protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT) when compared to the control cells, and was found to be related to CSC chemotherapy resistance. After Spearman regression correlation analysis, AGBL2 was observed to be related to clinical stage, histological stage, and lymph node metastasis. In the Cox regression test, the AGBL2 protein was detected as an independent prognostic factor. Through immunoprecipitation, AGBL2 and latexin could form immune complexes.

Conclusions

These results demonstrate that AGBL2 is a latexin-interacting protein that regulates the tubulin tyrosination cycle and is a potential target for intervention.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gaffan J, Dacre J, Jones A: Educating undergraduate medical students about oncology: a literature review. J Clin Oncol 2006, 24:1932-1939.
• [2]Dowling EC, Klabunde C, Patnick J: Ballard-Barbash R, for the International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 2010, 17:139-146.
• [3]Dilaveri CA, Mac Bride MB, Sandhu NP, Neal L, Ghosh K, Wahner-Roedler DL: Breast manifestations of systemic diseases. Int J Womens Health 2012, 4:35-43.
• [4]Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
• [5]Wang J, Cao MG, You CZ, Wang CL, Liu SL, Kai C, Dou J: A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol (Noisy-le-grand) 2012, 58:OL1641-OL1645.
• [6]Sahab ZJ, Hall MD, You Me S, Sivanesan D, Yun J, Deepak K, Byers SW: Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle. Cancer Res 2011, 71:1219-1228.
• [7]Arimatsu Y: Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res 1994, 20:131-135.
• [8]Hatanaka Y, Uratani Y, Takiguchi-Hayashi K, Omori A, Sato K, Miyamoto M, Arimatsu Y: Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 1994, 6:973-982.
• [9]Normant E, Gros C, Schwartz JC: Carboxypeptidase A isoforms produced by distinct genes or alternative splicing in brain and other extrapancreatic tissues. J Biol Chem 1995, 270:20543-20549.
• [10]Normant E, Martres MP, Schwartz JC, Gros C: Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor. Proc Natl Acad Sci U S A 1995, 92:12225-12229.
• [11]Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast cancer cells. N Engl J Med 2007, 356:217-226.
• [12]Ke Y, Xu GW, Hagiwara K, Zhang JM, Ning T, Wang B, Su XL, Feng LY, Lu GR, Lu YY, Harris CC: Isolation and sequencing of the target genes induced by chemical carcinogen. Science in China (Series C) 1996, 26:85-91.